Clinical impact of down-regulated plasma miR-92a levels in non-Hodgkin's lymphoma.

<h4>Background</h4>We undertook a study to evaluate the clinical relevance of miR-92a in plasma obtained from non-Hodgkin's lymphoma (NHL) patients, because the miR-17-92 polycistronic miRNA cluster plays a crucial role in lymphomagenesis and affects neo-angiogenesis.<h4>Metho...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kazuma Ohyashiki, Tomohiro Umezu, Sei-Ichiro Yoshizawa, Yoshikazu Ito, Michiyo Ohyashiki, Hisashi Kawashima, Masami Tanaka, Masahiko Kuroda, Junko H Ohyashiki
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2011
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/e6082c2af40a4251a0de894f087ed976
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e6082c2af40a4251a0de894f087ed976
record_format	dspace
spelling	oai:doaj.org-article:e6082c2af40a4251a0de894f087ed9762021-11-18T06:58:20ZClinical impact of down-regulated plasma miR-92a levels in non-Hodgkin's lymphoma.1932-620310.1371/journal.pone.0016408https://doaj.org/article/e6082c2af40a4251a0de894f087ed9762011-02-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21383985/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>We undertook a study to evaluate the clinical relevance of miR-92a in plasma obtained from non-Hodgkin's lymphoma (NHL) patients, because the miR-17-92 polycistronic miRNA cluster plays a crucial role in lymphomagenesis and affects neo-angiogenesis.<h4>Methodology/principal findings</h4>Plasma miR-92a values in NHL were extremely low (<5%), compared with healthy subjects (P<.0001), irrespective of lymphoma sub-type. The very low plasma level of miR-92a increased in the complete response (CR) phase but did not reach the normal range, and the plasma level was lower again in the relapse phase. Patients in CR or CR unconfirmed with a plasma miR-92a level of less than the cut-off level showed a significantly high relapse rate compared with patients with normalized plasma miR-92a level.<h4>Conclusions/significance</h4>The current results therefore indicate that the plasma miR-92a value could be a novel biomarker not only for diagnosis but also for monitoring lymphoma patients after chemotherapy.Kazuma OhyashikiTomohiro UmezuSei-Ichiro YoshizawaYoshikazu ItoMichiyo OhyashikiHisashi KawashimaMasami TanakaMasahiko KurodaJunko H OhyashikiPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 6, Iss 2, p e16408 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Kazuma Ohyashiki Tomohiro Umezu Sei-Ichiro Yoshizawa Yoshikazu Ito Michiyo Ohyashiki Hisashi Kawashima Masami Tanaka Masahiko Kuroda Junko H Ohyashiki Clinical impact of down-regulated plasma miR-92a levels in non-Hodgkin's lymphoma.
description	<h4>Background</h4>We undertook a study to evaluate the clinical relevance of miR-92a in plasma obtained from non-Hodgkin's lymphoma (NHL) patients, because the miR-17-92 polycistronic miRNA cluster plays a crucial role in lymphomagenesis and affects neo-angiogenesis.<h4>Methodology/principal findings</h4>Plasma miR-92a values in NHL were extremely low (<5%), compared with healthy subjects (P<.0001), irrespective of lymphoma sub-type. The very low plasma level of miR-92a increased in the complete response (CR) phase but did not reach the normal range, and the plasma level was lower again in the relapse phase. Patients in CR or CR unconfirmed with a plasma miR-92a level of less than the cut-off level showed a significantly high relapse rate compared with patients with normalized plasma miR-92a level.<h4>Conclusions/significance</h4>The current results therefore indicate that the plasma miR-92a value could be a novel biomarker not only for diagnosis but also for monitoring lymphoma patients after chemotherapy.
format	article
author	Kazuma Ohyashiki Tomohiro Umezu Sei-Ichiro Yoshizawa Yoshikazu Ito Michiyo Ohyashiki Hisashi Kawashima Masami Tanaka Masahiko Kuroda Junko H Ohyashiki
author_facet	Kazuma Ohyashiki Tomohiro Umezu Sei-Ichiro Yoshizawa Yoshikazu Ito Michiyo Ohyashiki Hisashi Kawashima Masami Tanaka Masahiko Kuroda Junko H Ohyashiki
author_sort	Kazuma Ohyashiki
title	Clinical impact of down-regulated plasma miR-92a levels in non-Hodgkin's lymphoma.
title_short	Clinical impact of down-regulated plasma miR-92a levels in non-Hodgkin's lymphoma.
title_full	Clinical impact of down-regulated plasma miR-92a levels in non-Hodgkin's lymphoma.
title_fullStr	Clinical impact of down-regulated plasma miR-92a levels in non-Hodgkin's lymphoma.
title_full_unstemmed	Clinical impact of down-regulated plasma miR-92a levels in non-Hodgkin's lymphoma.
title_sort	clinical impact of down-regulated plasma mir-92a levels in non-hodgkin's lymphoma.
publisher	Public Library of Science (PLoS)
publishDate	2011
url	https://doaj.org/article/e6082c2af40a4251a0de894f087ed976
work_keys_str_mv	AT kazumaohyashiki clinicalimpactofdownregulatedplasmamir92alevelsinnonhodgkinslymphoma AT tomohiroumezu clinicalimpactofdownregulatedplasmamir92alevelsinnonhodgkinslymphoma AT seiichiroyoshizawa clinicalimpactofdownregulatedplasmamir92alevelsinnonhodgkinslymphoma AT yoshikazuito clinicalimpactofdownregulatedplasmamir92alevelsinnonhodgkinslymphoma AT michiyoohyashiki clinicalimpactofdownregulatedplasmamir92alevelsinnonhodgkinslymphoma AT hisashikawashima clinicalimpactofdownregulatedplasmamir92alevelsinnonhodgkinslymphoma AT masamitanaka clinicalimpactofdownregulatedplasmamir92alevelsinnonhodgkinslymphoma AT masahikokuroda clinicalimpactofdownregulatedplasmamir92alevelsinnonhodgkinslymphoma AT junkohohyashiki clinicalimpactofdownregulatedplasmamir92alevelsinnonhodgkinslymphoma
_version_	1718424139707973632

Clinical impact of down-regulated plasma miR-92a levels in non-Hodgkin's lymphoma.

Ejemplares similares